I don't think it was discussed on the board - but realistically I don't see how that restriction would not be part of approval since:
a) HLA-2 status is known to be a factor in melanoma survival
b) HLA-2 is an immune system effector and the MOA of ipi is unambiguously immune based.
That said, I have been unable to track down the particular language/enrollment-restriction that is used in the clinical trials site. It doesn't call for HLA-2+ status, instead it calls for "HLA-A*0201 positive". Is A*201 a particular subtype of HLA-2? If so that would be a further restriction on the label. But not yet successful in decoding A*201.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.